FDA approved Casgevy CRISPR gene therapy for children as young as 2 with sickle cell disease on July 1, 2026. Here’s what families need to know about this milestone.
FDA Expands CRISPR Gene Therapy Casgevy to Children as Young as 2 with Sickle Cell Disease
by | Jul 21, 2026 | Uncategorized | 0 comments
Recent Comments